Kalkan Ismail Hakki, Sapmaz Ferdane, Güliter Sefa, Atasoy Pınar
Department of Gastroenterology, Kırıkkale University Faculty of Medicine, Attar Sokak 21/14 G.O.P., Çankaya, 06700, Ankara, Turkey.
Department of Pathology, Kırıkkale University Faculty of Medicine, Ankara, Turkey.
Wien Klin Wochenschr. 2016 May;128(9-10):329-34. doi: 10.1007/s00508-015-0896-2. Epub 2015 Dec 4.
In several studies, different risk factors other than antibiotic resistance have been documented with Helicobacter pylori eradication failure. We aimed in this study to investigate the relationship of gastric density of H. pylori, the occurrence/degree of gastric atrophy, and intestinal metaplasia (IM) with success rate of H. pylori eradication.
Two hundred consecutive treatment naive patients who received bismuth containing standart quadruple treatment due to H. pylori infection documented by histopathological examination of two antral or two corpal biopsies entered this retrospective study. The updated Sydney system was used to grade the activity of gastritis, density of H. pylori colonization, atrophy, and IM. Stages III and IV of operative link for gastritis assessment (OLGA) or the operative link on gastric intestinal metaplasia assessment (OLGIM) stages was considered as severe gastritis. H. pylori eradication was determined via stool H. pylori antigen test performed 4 weeks after the end of therapy.
The presence of gastric atrophy and IM was significantly higher in patients with eradication failure (p = 0.001 and 0.01, respectively). Severe gastritis (OLGA III-IV and OLGIM III-IV) rates were higher in eradication failure group. A multiple linear regression analysis showed that OLGA and OLGIM stages were to be independent risk factors for eradication failure (p = 0.03 and 0.01, respectively).
Our results suggested that histopathologically severe gastritis may cause H. pylori eradication failure. In addition, we found that H. pylori density was not a risk factor for treatment failure in patients who receive quadruple treatment.
在多项研究中,已记录到除抗生素耐药性之外的不同风险因素与幽门螺杆菌根除失败有关。本研究旨在探讨幽门螺杆菌的胃内密度、胃萎缩的发生/程度以及肠化生(IM)与幽门螺杆菌根除成功率之间的关系。
本回顾性研究纳入了200例连续的初治患者,这些患者因经两个胃窦或两个胃体活检组织病理学检查证实存在幽门螺杆菌感染而接受含铋剂的标准四联疗法。采用更新后的悉尼系统对胃炎活动度、幽门螺杆菌定植密度、萎缩和肠化生进行分级。胃炎评估手术链接(OLGA)的III期和IV期或胃肠化生评估手术链接(OLGIM)的III期和IV期被视为严重胃炎。在治疗结束4周后通过粪便幽门螺杆菌抗原检测确定幽门螺杆菌根除情况。
根除失败患者中胃萎缩和肠化生的发生率显著更高(分别为p = 0.001和0.01)。根除失败组的严重胃炎(OLGA III-IV和OLGIM III-IV)发生率更高。多元线性回归分析显示,OLGA和OLGIM分期是根除失败的独立危险因素(分别为p = 0.03和0.01)。
我们的结果表明,组织病理学上的严重胃炎可能导致幽门螺杆菌根除失败。此外,我们发现对于接受四联疗法的患者,幽门螺杆菌密度不是治疗失败的危险因素。